On Aug 10, Emcure’s shares climbed to ₹2,047.40, the highest level in a year. At 09:39 a.m., the stock was quoted at ₹2,015.00, up ₹37.90 or 1.92% on the BSE.
The company’s Sanand, Gujarat, formulation plant received an Establishment Inspection Report (EIR) from the U.S. Food & Drug Administration after an inspection carried out from 6 to 15 May 2026. The FDA classified the inspection as Voluntary Action Indicated (VAI) and has now closed the case.
Motilal Oswal keeps a ‘buy’ recommendation and a target price of ₹2,300. The brokerage raised its earnings estimates for FY27 by 7% and for FY28 by 2%, citing a strong ARV order book in other‑world markets, steady expansion in the EU segment, and improved growth in the DF segment.
For the June quarter, Emcure posted a 36.2% year‑on‑year jump in consolidated net profit, reaching ₹292 crore. Revenue rose 22.8% to ₹2,580 crore and EBITDA grew 25.8%, with the margin expanding 50 basis points to 19.7%.
In the previous session, the share closed at ₹1,977.10, up ₹41.00 or 2.12%. The stock has reached a 52‑week high of ₹2,008 and a low of ₹1,260.10, recorded on Aug 5 2026 and Sep 30 2025 respectively.
Today, the share trades 1.54% below its 52‑week peak and 56.9% above its low. Emcure’s market capitalisation stands at ₹37,501.66 crore.